Trastuzumab for example is an anti-HER2 monoclonal antibody used to treat breast cancer, and has been shown to make HER2+ tumour cells more susceptible to antibody dependent and T-cell mediated cytotoxicity (115, 116). This evidence concerns the gene ERBB2 and neoplasm.